innoVitro

What innoVitro does

innoVitro GmbH is a privately held German Contract Research Organization (CRO) headquartered in Jülich and founded in 2018. The company delivers human cell-based assay services for preclinical cardiac risk assessment, contractility measurement, electrophysiology, viability, and connectivity readouts using human iPSC-derived cardiomyocytes and advanced microphysiological systems (MPS). It serves pharmaceutical, biotechnology, nutritional, and academic research customers, including named relationships with Merck Healthcare KGaA, Bayer, Nexel, Nanion Technologies, University Hospital Zurich, and the University of Queensland.

The company operates three proprietary technology platforms that anchor its service offering: FLEXcyte 96, a 96-well plate with an elastic cell-culture substrate that fosters physiologically relevant maturation of mechano-sensitive stem-cell-derived cardiac models; CardioExcyte 96, a combined structural and contractile cardiac assay platform; and AtlaZ, an impedance-spectroscopy system for label-free, real-time live-cell monitoring across 576 wells simultaneously. These technologies support a portfolio of CRO service offerings covering safety/toxicology/efficacy screenings, cell-line characterization, and disease models (including human-based atrial fibrillation and dilated cardiomyopathy models), with study reports delivered in under eight weeks.

The business model is project-based, quote-driven professional services revenue, complemented by marketplace listings on Scientist.com and Science Exchange. Go-to-market relies on direct sales through enterprise engagement, supported by conference participation (SOT, SPS, ESTIV, Eurotox, MPS World Summit, ELRIG), the LabINAR scientific webinar series, peer-reviewed publications, and active memberships in HESI Cardiac Safety Committee, the Botanical Safety Consortium, and the 3Rs Collaborative. The company has 1-10 employees, no disclosed external funding or revenue, and appears to be founder/management-owned as a GmbH.

Name

innoVitro

Legal name

innoVitro GmbH

Website

https://innovitro.de

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

innoVitro GmbH is a German biotech CRO that delivers human cell-based assay services for preclinical cardiac safety, contractility, and electrophysiology using iPSC-derived cardiomyocytes on its proprietary FLEXcyte 96, CardioExcyte 96, and AtlaZ platforms, serving pharma, biotech, nutritional, and academic clients globally.

Ownership category

akta.pro rank

Product category

Preclinical Cardiac Safety CRO Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Cardiac safety screening
• Cell-based assays
• Preclinical drug testing
• IPSC cardiomyocytes
• Contract research services

Headquarters

HQ city

Jülich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: CRO services providing cell-based assay testing including cardiac safety assessments, toxicity evaluations, and efficacy studies for pharmaceutical, biotech, and nutritional industries. Services include functional, morphological, and electrophysiological cardiac liability screenings; cell line characterization; and custom disease model development. Turnaround time for study reports is under eight weeks.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

innoVitro operates as a Contract Research Organization (CRO) delivering human cell-based assay services for preclinical cardiac risk assessment in drug discovery. The company provides safety, toxicology, and efficacy screenings using human iPSC-derived cardiomyocytes and proprietary microphysiological systems, supported by three core technology platforms (FLEXcyte 96, CardioExcyte 96, and AtlaZ) that measure contractility, viability, connectivity, and electrophysiology. Services are custom-designed for pharmaceutical, biotechnology, and nutritional industry clients, with study reports typically delivered in under eight weeks.

Product overview

innoVitro is a Contract Research Organization (CRO) specializing in human-based cell analytics for drug discovery. The company offers a portfolio of three core technology platforms — FLEXcyte 96 (flexible substrate plates for cardiac contractility measurement), CardioExcyte 96 (cardiac electrophysiology), and AtlaZ (label-free live-cell analytics via impedance spectroscopy) — complemented by a suite of contract research services including safety/toxicology/efficacy screenings, cell line characterization, and custom disease models (Atrial Fibrillation, Dilated Cardiomyopathy). The offering is structured as technology platforms enabling CRO services rather than standalone software products.

Differentiator

Problem solved

Functional benefit

Brands

• FLEXcyte 96: 96-well plate with elastic substrate for mechano-sensitive cell culture and cardiac contractility measurements
• AtlaZ
• CardioExcyte 96

Products and services

• FLEXcyte 96 A 96-well plate technology with an elastic/flexible cell culture substrate designed for mechano-sensitive and mechano-active cells, enabling physiologically relevant maturation of stem cell-derived cardiomyocytes and direct contractility measurement for preclinical cardiac risk evaluation. Used by pharma/biotech clients and academic researchers for safety pharmacology.
• CardioExcyte 96 A cardiac assay technology platform that combines structural and contractile analysis capabilities for human iPSC-derived cardiomyocytes, supporting electrophysiological and contractile measurements in preclinical cardiac safety studies.
• AtlaZ A live-cell analytics system based on electrical impedance spectroscopy using 96-well plates with integrated gold electrodes, enabling label-free, real-time quantitative analysis of adherent cells across a frequency spectrum of 0.1 kHz to 100 kHz. Supports barrier integrity, cytolysis, cell monitoring, and TEER assessment across 576 wells simultaneously.
• Safety – Toxicology – Efficacy Screenings CRO cell-based assay services monitoring dynamic functional and cellular changes over time, covering contractile, morphological, and electrophysiological cardiac responses, plus broader toxicology and efficacy evaluations. Delivered to pharmaceutical, biotechnology, and nutritional industry clients.
• Cell Line Characterization Service profiling cell line identity, stability, and function to ensure reproducibility and assay relevance, including Functional Cardiac Characterization and Custom Non-Cardiac Characterization, delivered to biopharma and academic clients.
• Disease Models Custom in vitro disease models replicating key pathological mechanisms for predictive drug evaluation, including a Human-Based Atrial Fibrillation model, a Human-Based Dilated Cardiomyopathy (LMNA) model, and bespoke disease model design for client programs.

Quantifiable outcome

• Study reports delivered in under 8 weeks
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core, major and minor.

• CardiaTec BiocoreStrategic or Co-development Partner · 1 October 2025Grant-funded collaboration (Innovate UK and ZIM) starting October 2025 focused on hypertrophic cardiomyopathy (HCM) research. Combines innoVitro's human cell-based assays with CardiaTec's multiomics and computational analysis capabilities.
• Axol Bioscience Ltd.coreTechnology or IntegrationCollaboration on pharmacological characterization of atrial and ventricular hiPSC-derived cardiomyocytes. Joint presentation in LabINAR BREAK 3 on chamber-specific cardiomyocytes and their value for preclinical drug discovery.
• FUJIFILM Cellular Dynamics, Inc. (FCDI)coreTechnology or IntegrationCo-development on co-culture systems using iCell Cardiomyocytes2 with iCell Cardiac Fibroblasts on FLEXcyte 96. Joint publications and application notes on hybrid cell analysis for preclinical cardiac risk evaluation.
• Nanion TechnologiescoreTechnology or IntegrationStrategic technology partner providing complementary expertise in electrophysiology. Joint presentations at Nanion User Meetings, collaborative application notes comparing FLEXcyte 96 recordings with Musclemotion data. Nanion representative Sonja Stölzle-Feix serves as reference customer.
• HESI (Health and Environmental Sciences Institute)coreStrategic or Co-development PartnerActive membership in HESI Cardiac Safety Technical Committee and Stem Cell Working Group. Participation in collaborative initiatives including Botanical Safety Consortium working groups and NAM validation studies.
• Botanical Safety ConsortiummajorStrategic or Co-development PartnerActive participation in Cardiotox Working Group within the consortium founded by FDA, NIEHS, and HESI. Collaborative research on New Approach Methodologies (NAMs) for cardiotoxicity assessment of botanicals.
• 3RsC (3Rs Collaborative) MPS InitiativemajorStrategic or Co-development PartnerFeatured presenter in 3Rs Collaborative Heart MPS Webinar showcasing advancements in microphysiological systems for cardiac research. Promotes replacement, reduction, and refinement of animal testing.
• BayermajorTechnology or IntegrationListed as partner and client, indicating collaboration on cardiac safety assessment projects.
• MerckmajorTechnology or IntegrationReference customer for contractility services using human iPSC-derived cardiomyocytes. Testimonial highlights tailored studies and comprehensive study reports.
• Nexel Co., Ltd.coreTechnology or IntegrationKorean biotechnology company providing hiPSC-derived cardiomyocytes. CEO Choong-Seong Han provides testimonial on FLEXcyte value for product development and safety pharmacology research.
• Scientist.commajorChannel Partner/ Reseller/ DistributorMarketplace listing for innoVitro's CRO services, enabling discovery and procurement by pharmaceutical and biotech researchers globally.
• Science ExchangemajorChannel Partner/ Reseller/ DistributorMarketplace platform listing for innoVitro's services, providing access to research customers.
• University Hospital ZurichmajorTechnology or IntegrationAcademic collaboration with Prof. Dr. med. Jin Li's lab on autoimmune channelopathies research.
• MedLife eVminorStrategic or Co-development PartnerNon-profit medical research organization partnership.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Global CRO offering preclinical cardiac safety assessment and safety pharmacology services to large pharma — overlaps with innoVitro's CRO work but at vastly greater scale and breadth.
• Eurofins Discovery: Provides early-stage drug discovery services including cell-based cardiac safety/toxicology assays via Eurofins Panlabs, comparable CRO overlap with innoVitro's preclinical cardiac safety service offering.
• Evotec: Large Hamburg-based CRO/CDMO providing end-to-end preclinical through clinical services including iPSC-based cardiac safety — a broad incumbent whose cardiac safety offering competes with innoVitro's specialized CRO services for the same global pharma customers.

Emerging players

• TARA Biosystems (now part of Valo Health): Developed human cardiac tissue-on-a-chip disease models for preclinical efficacy and safety testing used by major pharma — directly comparable cardiac MPS / iPSC-based offering, recently integrated into Valo Health's AI-driven drug discovery platform.
• Insphero: Swiss company commercializing 3D microtissue / organ-on-chip models and related CRO services including cardiac applications — adjacent competitor in the NAM / MPS cardiac safety space serving pharma R&D.
• Curi Bio: Seattle-based company offering cardiac disease models via iPSC cardiomyocytes and microphysiological systems with engineered substrates and analytics, overlapping with innoVitro's MPS/cardiac contractility focus for translational drug discovery.

Direct peers

• Ncardia: Belgian/Dutch CRO specializing in iPSC-derived cardiomyocytes and preclinical cardiac safety assay services using both contractility and electrophysiology readouts — directly competitive with innoVitro's FLEXcyte 96 / CardioExcyte 96-based offering for pharma and biotech drug developers.
• Cyprotex (an Evotec company): Preclinical CRO with a dedicated cardiotoxicity services portfolio including iPSC cardiomyocyte assays for safety screening — a direct functional competitor in human-based cardiac risk assessment for pharma/biotech.
• Metrion Biosciences: UK-based preclinical CRO focused on cardiac safety and ion channel pharmacology using human iPSC-derived cardiomyocytes and manual patch-clamp/automated electrophysiology, serving the same pharma preclinical safety customer base as innoVitro.

Others

• Nanion Technologies: German instrumentation partner of innoVitro supplying the CardioExcyte 96 electrophysiology platform; while primarily an instrument vendor, Nanion also offers cell-based assay services and collaborates with pharma on cardiac safety — an enabling / adjacent peer rather than pure competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/innoVitroBio
• YouTubeyoutube.com/channel/UC0p4rk1mnQQPsSmG0Rm4NMw
• LinkedInlinkedin.com/company/innovitro

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about innoVitro